Palatin Technologies Inc.

ASE:PTN  
0.43
0.00 (+0.61%)
Other Pre-Announcement

Palatin Reports Fourth Quarter And Full Year Fiscal Year 2021 Financial Results

Published: 09/29/2021 11:40 GMT
Palatin Technologies Inc. (PTN) - Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate Update.
Palatin Technologies- Phase 3 Study of Pl9643 in Patients With Dry Eye Disease Expected to Start Next Quarter With Top-line Results Expected in H2 2022.
Palatin - Phase 2 Study of Pl8177 in Patients With Ulcerative Colitis Expected to Start Next Quarter With Top-line Results Expected in H2 2022.
Palatin Technologies - $60.1 Million in Cash and Cash Equivalents at June 30, 2021 - Projected Cash Runway Through Calendar 2022.
Palatin Technologies Inc - Qtrly Loss per Share $0.06.